XERIS BIOPHARMA HOLDINGS, INC. Operating Cash Flow
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Operating Cash Flow of $18.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $8.26M, a 4440.11% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $9.87M.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $20.04M, a 914.84% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $18.43M.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $28.63M.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$36.98M.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$47.02M.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$102.89M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $18.13M 10-Q · filed 2026-08-06 | $38.18M derived: sum of 3 quarters · filed 2026-08-06 | $56.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.87M 10-Q · filed 2026-05-07 | $29.91M derived: sum of 2 quarters · filed 2026-05-07 | $48.34M derived: sum of 3 quarters · filed 2026-05-07 | $48.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $38.48M derived: sum of 2 quarters · filed 2026-03-02 | $38.66M derived: sum of 3 quarters · filed 2026-08-06 | $28.63M 10-K · filed 2026-03-02 |
| 2025-09-30 | $18.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.61M derived: sum of 2 quarters · filed 2026-08-06 | $8.58M 10-Q · filed 2025-11-06 | $10.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $182.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$9.85M 10-Q · filed 2026-08-06 | -$7.87M derived: sum of 3 quarters · filed 2026-08-06 | -$16.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$10.03M 10-Q · filed 2026-05-07 | -$8.06M derived: sum of 2 quarters · filed 2026-05-07 | -$16.36M derived: sum of 3 quarters · filed 2026-05-07 | -$26.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$6.33M derived: sum of 2 quarters · filed 2026-03-02 | -$16.68M derived: sum of 3 quarters · filed 2026-03-02 | -$36.98M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$8.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$18.65M derived: sum of 2 quarters · filed 2025-11-06 | -$38.96M 10-Q · filed 2025-11-06 | -$31.48M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$10.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$30.65M 10-Q · filed 2025-08-07 | -$23.18M derived: sum of 3 quarters · filed 2026-03-02 | -$37.79M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$20.30M 10-Q · filed 2025-05-08 | -$12.83M derived: sum of 2 quarters · filed 2026-03-02 | -$27.44M derived: sum of 3 quarters · filed 2026-03-02 | -$41.19M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $7.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$7.14M derived: sum of 2 quarters · filed 2026-03-02 | -$20.88M derived: sum of 3 quarters · filed 2026-03-02 | -$47.02M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$14.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$28.35M derived: sum of 2 quarters · filed 2024-11-08 | -$54.49M 10-Q · filed 2024-11-08 | -$70.61M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$13.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$39.88M 10-Q · filed 2024-08-08 | -$56.00M derived: sum of 3 quarters · filed 2025-03-06 | -$73.76M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$26.14M 10-Q · filed 2024-05-09 | -$42.26M derived: sum of 2 quarters · filed 2025-03-06 | -$60.01M derived: sum of 3 quarters · filed 2025-03-06 | -$80.62M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$16.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$33.87M derived: sum of 2 quarters · filed 2025-03-06 | -$54.48M derived: sum of 3 quarters · filed 2025-03-06 | -$102.89M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$17.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$38.36M derived: sum of 2 quarters · filed 2023-11-09 | -$86.77M 10-Q · filed 2023-11-09 | -$115.72M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$20.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$69.02M 10-Q · filed 2023-08-08 | -$97.96M derived: sum of 3 quarters · filed 2024-03-06 | -$120.58M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$48.41M 10-Q · filed 2023-05-09 | -$77.36M derived: sum of 2 quarters · filed 2024-03-06 | -$99.97M derived: sum of 3 quarters · filed 2024-03-06 | -$119.99M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$28.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$51.56M derived: sum of 2 quarters · filed 2024-03-06 | -$71.58M derived: sum of 3 quarters · filed 2024-03-06 | -$95.53M 10-K · filed 2024-03-06 |
| 2021-09-30 | -$22.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$42.63M derived: sum of 2 quarters · filed 2022-11-09 | -$66.59M 10-Q · filed 2022-11-09 | -$77.46M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$20.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$43.98M 10-Q · filed 2022-08-10 | -$54.85M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | -$23.96M 10-Q · filed 2022-05-11 | -$34.83M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | -$10.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$80.56M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | -$69.69M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |